Charalampos S Floudas

Nov 18, 2024 | nature.com | Qiao Jin |Charalampos S Floudas |Fangyuan Chen |Yifan Yang |Jimeng Sun |Changlin Gong

AbstractPatient recruitment is challenging for clinical trials. We introduce TrialGPT, an end-to-end framework for zero-shot patient-to-trial matching with large language models. TrialGPT comprises three modules: it first performs large-scale filtering to retrieve candidate trials (TrialGPT-Retrieval); then predicts criterion-level patient eligibility (TrialGPT-Matching); and finally generates trial-level scores (TrialGPT-Ranking).

Nov 17, 2024 | flipboard.com | Qiao Jin |Zifeng Wang |Charalampos S Floudas |Fangyuan Chen |Changlin Gong |Dara Bracken-Clarke | +4 more

4 hours agoHas AI Killed Graphic Design Jobs? The rapid advancement of generative AI technologies has undeniably transformed various sectors, including the field of graphic design.

Nov 5, 2024 | ejnmmires.springeropen.com | Fahmida Haque |Jorge Carrasquillo |Evrim Turkbey |Esther Mena |Liza Lindenberg |Naris Nilubol | +6 more

In this study, three independent clinical trial populations were used to develop and validate the AI model. Detailed information about the DOTATATE PET/CT scans of all three cohorts is listed in Table 1. The first cohort consists of 38 adult patients undergoing Lu-177-DOTATATE treatment for inoperable, metastatic, and histologically proven Pheochromocytoma/Paraganglioma (NCT03206060), referred to as PPGL cohort for the remainder of the study.